ストックスクリーナーアプリを入手
328.97
1.44%
4.67
プレマーケット:
328.10
-0.87
-0.26%
Amgen Inc (AMGN) 最新ニュース
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - sharewise.com
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses - Benzinga
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate - Yahoo Finance
Amgen Inc. $AMGN Shares Acquired by Global Wealth Management Investment Advisory Inc. - MarketBeat
Decliners Report: Why Amgen Inc stock could rally in 20252025 Breakouts & Breakdowns & Weekly Top Performers Watchlists - moha.gov.vn
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman - Benzinga
Ro partners with Amgen to study barriers to obesity care, GLP-1 access - marketscreener.com
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance - FinancialContent
Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage - marketscreener.com
Amgen (AMGN) Reveals Promising Results from MariTide Phase 2 Stu - GuruFocus
Amgen Inc. $AMGN Shares Acquired by PKO Investment Management Joint Stock Co - MarketBeat
Nordea Investment Management AB Acquires 22,465 Shares of Amgen Inc. $AMGN - MarketBeat
Trickle of Data On Amgen’s MariTide Hints At Potential Of Lower Maintenance Dosing - Citeline News & Insights
Amgen to announce data on obesity drug MariTide at healthcare conference - WNWN-FM
Amgen Inc. $AMGN Shares Bought by Citizens Financial Group Inc. RI - MarketBeat
Amgen says MariTide helped trial patients maintain weight loss - The Mighty 790 KFGO
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules - BioSpace
Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event - MarketBeat
Amgen’s MariTide Patients Maintain Weight Loss for Two Years - Bloomberg.com
Amgen's Maritide: A Breakthrough in Diabetes Management - Devdiscourse
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight - TradingView — Track All Markets
Key Executive Transition from Amgen (AMGN) to BioMarin - GuruFocus
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Lobbying Update: $37,500 of AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. $AMGN Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Meeder Asset Management Inc. Purchases 27,584 Shares of Amgen Inc. $AMGN - MarketBeat
Tema Etfs LLC Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
First Horizon Corp Takes Position in Amgen Inc. $AMGN - MarketBeat
Amgen Buys U.K. Biotech Company - Los Angeles Business Journal
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors - simplywall.st
Amgen Stock Holds Its Ground: What The Latest Price Action, Ratings and Pipeline Signals Mean For In - AD HOC NEWS
Amgen stock slides into weekend as JPMorgan healthcare conference looms - TechStock²
Nepsis Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After Its 28% One Year Share Price Gain? - Yahoo Finance
Amgen to acquire Dark Blue for cancer drug DBT 3757 - BioXconomy
State of Alaska Department of Revenue Sells 3,034 Shares of Amgen Inc. $AMGN - MarketBeat
Oregon Public Employees Retirement Fund Buys 15,172 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Nova R Wealth Inc. - MarketBeat
Amgen (NASDAQ:AMGN) Stock Rating Upgraded by UBS Group - MarketBeat
Amgen Inc. $AMGN Shares Bought by Ferguson Wellman Capital Management Inc. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) aligns with nasdaq composite life sciences - Kalkine Media
Can Amgen Inc. stock rebound after recent weaknessQuarterly Earnings Report & Technical Pattern Based Signals - ulpravda.ru
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
How Amgen Inc. stock valuations compare to rivalsWeekly Profit Report & Growth Oriented Trading Recommendations - ulpravda.ru
Amgen (AMGN) Valuation Check After DISCO Oncology Deal And Fresh Analyst Optimism - simplywall.st
Amgen (NASDAQ:AMGN) Price Target Raised to $319.00 at Truist Financial - MarketBeat
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating - MarketScreener
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan - TipRanks
Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? - Yahoo Finance
Amgen acquires British Dark Blue Therapeutics for USD 840m - medwatch.com
SG Americas Securities LLC Has $79.95 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by HB Wealth Management LLC - MarketBeat
Evotec benefits from Dark Blue acquisition by Amgen - European Biotechnology Magazine
Biotech Amgen acquires UK-based Dark Blue Therapeutics in $840m deal - Silicon Republic
Amgen Inc.: How a Biotech Powerhouse Is Re-Architecting Its Drug Platform for the Next Decade - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by Benjamin Edwards Inc. - MarketBeat
Call for Application for 2026 Tsinghua Amgen Scholars Program - PR Newswire
Humira Market to Witness Remarkable Growth With AbbVie Inc., Amgen Inc., Samsung Bioepis - openPR.com
1.90%
1.22%
大文字化:
|
ボリューム (24 時間):